Pancreatic cancer

Showing 15 posts of 24 posts found.

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …

Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins

May 18, 2023
Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …


Lynparza secures CHMP recommendation in first-line BRCA-mutated metastatic pancreatic cancer

June 1, 2020
Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza

Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has just secured recommendation for approval from the European Medicines …


Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

February 19, 2020
Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …


FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019
Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …

Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer

October 17, 2019
Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma

In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …


Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show

April 3, 2019
Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma

At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …


Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

February 26, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …


NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

August 4, 2017
Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals

Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …


UK underperforming in cancer care compared to Europe, according to ABPI report

July 18, 2017
Research and Development ABPI, Cancer, Pancreatic cancer, biotech, heralthcare, lung cancer, ovarian cancer, pharma, pharmaceutical

According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …


NICE turns down Shire’s pancreatic cancer treatment

April 4, 2017
Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire

NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment …


Cancer Research UK announces £10m pancreatic cancer project

March 24, 2017
Medical Communications, Research and Development Cancer Research UK, Pancreatic cancer

Cancer Research UK has revealed a £10 million investment into PRECISION-Panc, a pancreatic cancer-focused project which aims to improve patient …


Breakthrough treatment for pancreatic cancer doubles survival rates

January 25, 2017
Research and Development CRUK, Cancer Research UK, Pancreatic cancer

Research led by Liverpool University and funded by Cancer Research UK has shown that a combination treatment of two off-patent …


Shire receives positive EU opinion for pancreatic cancer drug

July 25, 2016
Research and Development, Sales and Marketing CHMP, EU, Pancreatic cancer, Shire

Shire has announced that the EU regulator’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion …


Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge

May 17, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …

Latest content